Artal Group’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Artal Group’s Portfolio ORTX Stock Details ORTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-180,386	Closed	-$669K	–	149
2022 Q4	$669K	Hold	180,386	–	–	0.04%	113
2022 Q3	$902K	Hold	180,386	–	–	0.04%	118
2022 Q2	$1.05M	Hold	180,386	–	–	0.06%	116
2022 Q1	$1.28M	Hold	180,386	–	–	0.05%	119
2021 Q4	$2.38M	Hold	180,386	–	–	0.06%	128
2021 Q3	$4.15M	Hold	180,386	–	–	0.09%	118
2021 Q2	$7.92M	Hold	180,386	–	–	0.16%	101
2021 Q1	$13.1M	Buy	180,386 +145,236	+413%	+$10.3M	0.23%	85
2020 Q4	$1.52M	Hold	35,150	–	–	0.03%	125
2020 Q3	$1.45M	Sell	35,150 -1,850	-5%	-$95.6K	0.04%	127
2020 Q2	$2.22M	Sell	37,000 -3,000	-8%	-$275K	0.06%	122
2020 Q1	$3.01M	Buy	40,000 +5,000	+14%	+$576K	0.13%	92
2019 Q4	$4.81M	Hold	35,000	–	–	0.19%	73
2019 Q3	$4.16M	Hold	35,000	–	–	0.17%	78
2019 Q2	$4.9M	Buy	+35,000	New	+$6.15M	0.2%	80

Other funds holding ORTX

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Kapitalo Investimentos Sao Paulo, Brazil $1.58B AUM 19.49% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Artal Group's ORTX Position: Q1 2023 in Review

Artal Group sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q1 2023, closing a stake of 180,386 shares — an estimated $669K sold.

Artal Group first reported a position in ORTX in Q2 2019 and held it in 15 quarters. The position peaked at $13.1M in Q1 2021. 35 funds tracked by Wall St. Rank hold ORTX as of Q1 2023.

Artal Group reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q1 2023 after selling out during the quarter.
Artal Group sold 180,386 Orchard Therapeutics plc American Depositary Shares shares in Q1 2023, an estimated $669K.
Artal Group first reported a position in Orchard Therapeutics plc American Depositary Shares in Q2 2019 and held it in 15 quarters.
Artal Group's Orchard Therapeutics plc American Depositary Shares position peaked at $13.1M in Q1 2021.
35 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q1 2023.

Based on Artal Group's 13F filing for Q1 2023, filed 12 May 2023.